|
WO2008031264A1
|
|
Furost-5-ene-3, 22, 26-triol glycoside compound for preventing and treating cancer
|
|
KR20090058542A
|
|
Furost-5-ene-3,22,26-triol glycoside compound for preventing and treating cancer
|
|
WO2008028314A1
|
|
Catechol derivatives, composition and application thereof
|
|
US2010172986A1
|
|
Controlled release composition and preparation thereof
|
|
CN101484150A
|
|
Controlled release composition and preparation thereof
|
|
CA2551690A1
|
|
Compositions for use with skin
|
|
US2006222689A1
|
|
Skin care compositions and methods
|
|
WO2007134485A1
|
|
Aporphine and oxoaporphine compounds and pharmaceutical use thereof
|
|
ZA200509183B
|
|
Topical composition for transdermal administration
|
|
TW200701990A
|
|
Composition for improving an area of skin hydration and method thereof
|
|
CN1884265A
|
|
Aporphine for treating diabetes mellitus and aporphine compounds
|
|
TW200642686A
|
|
Aporphine or secoaporphine compounds for treatment of diabetes
|
|
CN1679955A
|
|
Compositions for improving drug safety
|
|
TW200633729A
|
|
Pharmaceutical composition for enhancing medication safety
|
|
KR20070007166A
|
|
Oral modified-release lozenges and their preparation method
|
|
AU2004318976A1
|
|
Oral modified-release lozenges and their preparation method
|
|
CN1689556A
|
|
Oral administered sustained release lozenge composition and its preparation method
|
|
TW200526271A
|
|
Composition for a modified-release oral tablet and method for manufacturing of the composition
|
|
TWI227238B
|
|
Novel pyranocoumarin compounds and their applications
|
|
KR20060089135A
|
|
Aporphine and oxoaporphine and the medical use thereof
|
